{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:54:14Z","timestamp":1775130854922,"version":"3.50.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>In vitro fertilization is indicated for infertile women with polycystic ovarian syndrome (PCOS) after unsuccessful treatment with ovulation induction agents or in women deemed high-risk of multiple gestations who are ideal candidates for single embryo transfers. PCOS patients are at increased risk of ovarian hyperstimulation syndrome; therefore, attention should be made in the choice of in vitro fertilization treatment protocol, dose of gonadotropin utilized, and regimen to achieve final oocyte maturation. Adopting these strategies in addition to close monitoring may significantly reduce the ovarian hyperstimulation syndrome risk. Future developments may improve pregnancy outcomes and decrease complications in PCOS women undergoing fertility treatment.<\/jats:p>","DOI":"10.1097\/grf.0000000000000561","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:18:50Z","timestamp":1611267530000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro Fertilization for Polycystic Ovarian Syndrome"],"prefix":"10.1097","volume":"64","author":[{"given":"JESSICA R.","family":"ZOLTON","sequence":"first","affiliation":[{"name":"Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SAIOA","family":"TORREALDAY","sequence":"additional","affiliation":[{"name":"Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.fertnstert.2019.09.042","article-title":"Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis","volume":"113","author":"Zolton","year":"2020","journal-title":"Fertil Steril"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/humupd\/dmi036","article-title":"A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome","volume":"12","author":"Heijnen","year":"2006","journal-title":"Hum Reprod Update"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.rbmo.2018.05.003","article-title":"Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters","volume":"37","author":"De Vos","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1472-6483(10)60040-5","article-title":"Symposium: update on prediction and management of OHSS. Epidemiology of OHSS","volume":"19","author":"Delvigne","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor","volume":"87","author":"Wang","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil Steril"},{"key":"R8-20250512","first-page":"233","article-title":"Assisted reproductive technology in Europe, 2011: results generated from European registers by ESHRE","volume":"31","author":"Kupka","year":"2016","journal-title":"Hum Reprod"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.fertnstert.2008.08.127","article-title":"Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization","volume":"92","author":"Nardo","year":"2009","journal-title":"Fertil Steril"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1210\/jcem-71-4-918","article-title":"Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization","volume":"71","author":"Gonen","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250512","first-page":"1382","article-title":"Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study","volume":"10","author":"Olivennes","year":"1995","journal-title":"Hum Reprod"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/humupd\/dmr008","article-title":"GnRH agonist for triggering of final oocyte maturation: time for a change of practice?","volume":"17","author":"Humaidan","year":"2011","journal-title":"Hum Reprod Update"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/humrep\/dep436","article-title":"Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)","volume":"25","author":"Lainas","year":"2010","journal-title":"Hum Reprod"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-Free Clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/humrep\/deh765","article-title":"GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF\/ICSI cycles: a prospective randomized study","volume":"20","author":"Humaidan","year":"2005","journal-title":"Hum Reprod"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.fertnstert.2018.02.003","article-title":"Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter?","volume":"109","author":"Benadiva","year":"2018","journal-title":"Fertil Steril"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.fertnstert.2015.09.015","article-title":"Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles?","volume":"105","author":"Healy","year":"2016","journal-title":"Fertil Steril"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1513873","article-title":"Fresh versus frozen embryos for infertility in the polycystic ovary syndrome","volume":"375","author":"Chen","year":"2016","journal-title":"N Engl J Med"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1933719114561552","article-title":"Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation","volume":"22","author":"Schulte","year":"2015","journal-title":"Reprod Sci"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rbmo.2016.04.006","article-title":"Low aneuploidy rate in early pregnancy loss abortuses from patients with polycystic ovary syndrome","volume":"33","author":"Wang","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.fertnstert.2019.01.026","article-title":"Higher chromosomal aberration rate in miscarried conceptus from polycystic ovary syndrome women undergoing assisted reproductive treatment","volume":"111","author":"Li","year":"2019","journal-title":"Fertil Steril"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1095\/biolreprod66.2.297","article-title":"Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome","volume":"66","author":"Apparao","year":"2002","journal-title":"Biol Reprod"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1530\/REP-18-0583","article-title":"Obesity induces ovarian inflammation and reduces oocyte quality","volume":"158","author":"Snider","year":"2019","journal-title":"Reproduction"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","article-title":"Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome","volume":"162","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/humrep\/der154","article-title":"Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study","volume":"26","author":"Kjotrod","year":"2011","journal-title":"Hum Reprod"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/humrep\/del025","article-title":"The use of metformin for women with PCOS undergoing IVF treatment","volume":"21","author":"Tang","year":"2006","journal-title":"Hum Reprod"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"hoy021","DOI":"10.1093\/hropen\/hoy021","article-title":"Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility","volume":"2019","author":"Costello","year":"2019","journal-title":"Hum Reprod Open"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1210\/jc.2006-2846","article-title":"Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women","volume":"92","author":"Stanek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.fertnstert.2011.09.020","article-title":"Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial","volume":"96","author":"Palomba","year":"2011","journal-title":"Fertil Steril"},{"key":"R31-20250512","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13048-018-0392-1","article-title":"Metformin improves ovarian follicle dynamics by reducing theca cell proliferation and CYP-17 expression in an androgenized rat model","volume":"11","author":"Mahamed","year":"2018","journal-title":"J Ovarian Res"},{"key":"R32-20250512","first-page":"CD006105","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","author":"Tso","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.fertnstert.2014.07.1240","article-title":"Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists","volume":"102","author":"Ferrero","year":"2014","journal-title":"Fertil Steril"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Hum Reprod"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.fertnstert.2013.11.005","article-title":"Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Leitao","year":"2014","journal-title":"Fertil Steril"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/humrep\/16.11.2263","article-title":"Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome","volume":"16","author":"Papaleo","year":"2001","journal-title":"Hum Reprod"},{"key":"R37-20250512","first-page":"CD002811","article-title":"Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome","volume":"5","author":"D\u2019Angelo","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14647270600787575","article-title":"The optimal length of \u2018coasting protocol\u2019 in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization","volume":"9","author":"Nardo","year":"2006","journal-title":"Hum Fertil"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.fertnstert.2016.03.013","article-title":"Can we modify assisted reproductive technology practice to broaden reproductive care access?","volume":"105","author":"Paulson","year":"2016","journal-title":"Fertil Steril"},{"key":"R40-20250512","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/humrep\/deu248","article-title":"In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes","volume":"30","author":"Walls","year":"2015","journal-title":"Hum Reprod"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.fertnstert.2012.04.046","article-title":"In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles","volume":"98","author":"Gremeau","year":"2012","journal-title":"Fertil Steril"},{"key":"R42-20250512","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.rbmo.2010.05.002","article-title":"Chromosome abnormality rates in human embryos obtained from in-vitro maturation and IVF treatment cycles","volume":"21","author":"Zhang","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"R43-20250512","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/sj.ejhg.5200990","article-title":"In vitro follicular growth affects oocyte imprinting establishment in mice","volume":"11","author":"Kerjean","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"R44-20250512","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.fertnstert.2019.05.034","article-title":"Obstetrical, neonatal, and long-term outcomes of children conceived from in vitro matured oocytes","volume":"112","author":"Yu","year":"2019","journal-title":"Fertil Steril"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:18:13Z","timestamp":1747063093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000561","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,28]]}}}